Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 18/20 | 0.49 |
| ▸ | PFKFB1 | P16118 | 17/20 | 0.49 |
| ▸ | PFKFB2 | O60825 | 15/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095374 | 0.89 | PFKFB3 (0.53) | PFKFB3PFKFB1PFKFB2 | |
| SCHEMBL10249312 | 0.88 | MTNR1A (0.42) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL10249955 | 0.87 | MTNR1A (0.46) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13152055 | 0.82 | MTNR1A (0.46) | PFKFB3PFKFB1PFKFB2MEN1NPC1 | |
| SCHEMBL10097656 | 0.82 | PFKFB2 (0.48) | PFKFB3PFKFB1PFKFB2MEN1NPC1 | |
| SCHEMBL13153378 | 0.81 | NPC1 (0.42) | PFKFB3PFKFB1PFKFB2MEN1NPC1 | |
| SCHEMBL13152172 | 0.80 | MAPT (0.44) | PFKFB3PFKFB1PFKFB2MEN1NPC1 | |
| SCHEMBL10097607 | 0.80 | MTNR1A (0.46) | PFKFB3PFKFB1PFKFB2MEN1NPC1 | |
| SCHEMBL10097782 | 0.79 | L3MBTL1 (0.42) | PFKFB3PFKFB1PFKFB2MEN1NPC1 | |
| SCHEMBL13151697 | 0.79 | ALDH1A1 (0.42) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | PFKFB3 4055/4885PFKFB1 4133/4885PFKFB2 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.